Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

39.60
-0.5000-1.25%
Volume:238.37K
Turnover:9.38M
Market Cap:3.81B
PE:-20.24
High:40.16
Open:39.85
Low:38.90
Close:40.10
52wk High:42.68
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.68
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.18
PE(LYR):-30.82

Loading ...

Ideaya Biosciences, Inc. : Leerink Partners Cuts Target Price to $31 from $37

THOMSON REUTERS
·
Aug 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 05

IDEAYA Biosciences (IDYA) Stock Faces Loss Pressure Despite Revenue Traction

Simply Wall St.
·
Aug 05

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and TransMedics Group (TMDX)

TIPRANKS
·
Aug 05

Wedbush Adjusts Price Target on IDEAYA Biosciences to $60 From $58, Maintains Outperform Rating

MT Newswires Live
·
Aug 04

Ideaya Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q2 Net Loss $1.22 a Share, vs. FactSet Est of $1.18 Loss

MT Newswires Live
·
Aug 04

IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate

Benzinga Earnings
·
Aug 04

Ideaya Q2 FY26 Net Loss Widens to $112.45 Million; Revenue Rises 35.02% to $8.86 Million vs Q1 FY26

Reuters
·
Aug 04

Ideaya Biosciences Q2 Operating Expenses USD 131.148 Million

THOMSON REUTERS
·
Aug 04

Press Release: Ideaya Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 04

Ideaya Biosciences Grants 260,200 Inducement Stock Options at $36.4 Per Share

Reuters
·
Jul 31

Ideaya Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 31

Will IDEAYA’s (IDYA) IDE892 Combo Strategy in MTAP‑Deleted Cancers Reshape Its Targeted Oncology Narrative?

Simply Wall St.
·
Jul 30

IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target Maintained

TIPRANKS
·
Jul 27

Ideaya Biosciences initiates monotherapy expansion in IDE892 trial

TIPRANKS
·
Jul 27

Ideaya Begins Phase 1/2 Part 2 Monotherapy Expansion of Ide892 in MTAP-deleted Pancreatic, Lung Cancers

Reuters
·
Jul 27

Ideaya Biosciences Announces Ide892, a Potential Best-in-Class Mta-Cooperative Prmt5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in Mtap-Deleted Pancreatic and Lung Cancers

THOMSON REUTERS
·
Jul 27

Ideaya Shares ESMO 2026 Data Updates for Darovasertib Trials in Uveal Melanoma

Reuters
·
Jul 17

Ideaya Biosciences Chief Accounting Officer Andres Ruiz Briseno Sells 9,550 Shares for $382,131.94

Reuters
·
Jul 10